Rethinking Risk-Benefit Assessment for Phase I Multiple Myeloma Trials

被引：0
|
作者：
Malek, Ehsan [1 ]
Saygin, Caner [2 ]
Ye, Rebecca [3 ]
Kim, Byung-gyu [4 ]
Covut, Fahrettin [1 ]
De Lima, Marcos [1 ]
Driscoll, James J. [5 ]
机构：
[1] Univ Hosp Case Med Ctr, Adult Hematol Malignancies & Stem Cell Transplant, Seidman Canc Ctr, Cleveland, OH USA
[2] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA
[3] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[4] Case Western Reserve Univ, Dept Pediat, Case Comprehens Canc Ctr, Cleveland, OH USA
[5] Univ Cincinnati, Coll Med, Canc Ctr, Cincinnati, OH USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1146.1146
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1146
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Rethinking risk-benefit assessment for phase I cancer trials
    Joffe, Steven
    Miller, Franklin G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 2987 - 2990
  • [2] Details of risk-benefit communication in informed consent documents for phase I/II trials
    Kahrass, Hannes
    Bossert, Sabine
    Schurmann, Christopher
    Strech, Daniel
    [J]. CLINICAL TRIALS, 2021, 18 (01) : 71 - 80
  • [3] Risk-benefit assessment of glatiramer acetate in multiple sclerosis
    Ziemssen, T
    Neuhaus, O
    Hohlfeld, R
    [J]. DRUG SAFETY, 2001, 24 (13) : 979 - 990
  • [4] Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis
    Tjalf Ziemssen
    Oliver Neuhaus
    Reinhard Hohlfeld
    [J]. Drug Safety, 2001, 24 : 979 - 990
  • [5] Rethinking Risk-Benefit Evaluations in Biomedical Research
    Rid, Annette
    [J]. ETHICS AND GOVERNANCE OF BIOMEDICAL RESEARCH: THEORY AND PRACTICE, 2016, 4 : 153 - 162
  • [6] EVALUATING RISK-BENEFIT IN DRUG TRIALS
    LEVINE, MAH
    BROWMAN, G
    SACKETT, DL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (02) : 126 - 126
  • [7] Risk-Benefit Assessment of Foods
    Assuncao, R.
    Pires, S. M.
    Nauta, M.
    [J]. EFSA JOURNAL, 2019, 17
  • [8] Risk-benefit trade-offs and precision utilities in phase I-II clinical trials
    Msaouel, Pavlos
    Lee, Juhee
    Thall, Peter F.
    [J]. CLINICAL TRIALS, 2024, 21 (03) : 287 - 297
  • [9] A Risk-Benefit Assessment of Amifostine in Cytoprotection
    May Mabro
    Sandrine Faivre
    Eric Raymond
    [J]. Drug Safety, 1999, 21 : 367 - 387
  • [10] A Risk-Benefit Assessment of Antileukotrienes in Asthma
    Lewis J. Smith
    [J]. Drug Safety, 1998, 19 : 205 - 218
12345